The Acute Lung Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Lung Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued products.
GlobalData tracks 50 drugs in development for Acute Lung Injury by 47 companies/universities/institutes. The top development phase for Acute Lung Injury is preclinical with 31 drugs in that stage. The Acute Lung Injury pipeline has 39 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Acute Lung Injury pipeline products market are: University of Seville, BioSuperior Technology and Ceria Therapeutics.
The key targets in the Acute Lung Injury pipeline products market include Angiopoietin 1 Receptor, Angiotensin Converting Enzyme 2, and Apoptosis Associated Speck Like Protein Containing A CARD.
The key mechanisms of action in the Acute Lung Injury pipeline product include Dipeptidyl Peptidase 4 Inhibitor with one drug in Preclinical. The Acute Lung Injury pipeline products include nine routes of administration with the top ROA being Intravenous and 13 key molecule types in the Acute Lung Injury pipeline products market including Small Molecule, and Monoclonal Antibody.
Acute Lung Injury overview
Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke, or severe lung infections; or indirect causes, including sepsis (severe infection), severe trauma, multiple blood transfusions, pancreatitis, or other systemic conditions that lead to widespread inflammation. ALI involves injury to the alveoli (air sacs) and the surrounding lung tissues, causing increased permeability of the alveolar-capillary membrane. This leads to fluid accumulation in the lungs (pulmonary edema), impairing oxygen exchange between the air sacs and blood vessels. Common signs and symptoms of acute lung injury may include severe difficulty breathing or shortness of breath (dyspnea); rapid breathing (tachypnea) and rapid heart rate (tachycardia); severe fatigue, weakness, or confusion due to decreased oxygen levels in the blood; and cyanosis (bluish discoloration of the skin) due to lack of oxygen.
For a complete picture of Acute Lung Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
